Evolus is growing revenue 21% YoY with an 86.2% gap to the analyst target and a 3-of-4 earnings beat record, but it is cash-burning, relies on two single-source suppliers, and has insiders selling.
Thesis pillars
- Cash Burn Margin Compression↓Deteriorating
- Strong Revenue Growth→Stable
- Supplier Concentration Risk↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 3, 2026
Evolus, Inc. Common Stock (EOLS) Stock Analysis
Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $7.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 9.00; Below-average business quality.
Evolus, Inc. is a global performance beauty company selling Jeuveau®, an injectable botulinum toxin type A for frown lines, and Evolysse™, a line of injectable hyaluronic acid gel fillers, to licensed aesthetic practitioners in the cash-pay aesthetic market. The company... Read more
Sell if holding. Engine safety override at $7.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 9.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — Evolus, Inc. Common Stock
Latest news
- NEWS Evolus Management to Participate in Upcoming Investor Conferences — fiscal.ai Oct 28, 2026 neutral
- NEWS Evolus, Inc. Schedules Third Quarter 2026 Financial Results Announcement — fiscal.ai Oct 21, 2026 neutral
- NEWS Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug — benzinga Oct 2, 2026 negative
- NEWS FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As Misleading — benzinga Oct 2, 2026 negative
- NEWS Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role — benzinga Sep 1, 2026 neutral
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierDaewoong (Jeuveau manufacturer)10-K Item 1: 'Daewoong Pharmaceuticals Co. Ltd. ("Daewoong") manufactures and supplies Jeuveau® to us.'
- HIGHSupplierSymatese (Evolysse manufacturer)10-K Item 1: 'Symatese Aesthetics S.A.S. ("Symatese") manufactures and supplies Evolysse™ to us.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -10.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 9.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $7.10. Score 6.3/10, moderate confidence.
Analyst target: $13.05 (+70.9% upside). Prior stop was $7.10. Stop-loss: $7.10.
Concentration risk — Supplier: Daewoong (Jeuveau manufacturer); Concentration risk — Supplier: Symatese (Evolysse manufacturer); Quality below floor (3.6 < 4.0).
Evolus, Inc. Common Stock trades at a P/E of N/A (forward 26.1). TrendMatrix value score: 8.4/10. Verdict: Sell.
12 analysts cover EOLS with a consensus score of 4.3/5. Average price target: $15.
What does Evolus, Inc. Common Stock do?Evolus, Inc. is a global performance beauty company selling Jeuveau®, an injectable botulinum toxin type A for frown...
Evolus, Inc. is a global performance beauty company selling Jeuveau®, an injectable botulinum toxin type A for frown lines, and Evolysse™, a line of injectable hyaluronic acid gel fillers, to licensed aesthetic practitioners in the cash-pay aesthetic market. The company generates revenue from direct-to-practitioner sales in the U.S., Canada, Europe, and Australia, with Jeuveau® manufactured exclusively by Daewoong Pharmaceutical in South Korea and Evolysse™ manufactured exclusively by Symatese in France.